Abstract
Driven by complex and interconnected factors, including population growth, climate change and geopolitics, infectious dis-eases represent one of the greatest healthcare challenges of the 21st century. Diagnostic technologies are the first line of de-fense in the fight against infectious disease, providing critical information to inform epidemiological models, track diseases, decide treatment choices and ultimately prevent epidemics. The diagnosis of infectious disease at the genomic level using nucleic acid disease biomarkers has proven to be the most effective approach to date. Such methods rely heavily on enzymes to specifically amplify or detect nucleic acids in complex samples, and significant effort has been exerted to harness the pow-er of enzymes for in vitro nucleic acid diagnostics. Unfortunately, significant challenges limit the potential of enzyme-assisted nucleic acid diagnostics, particularly when translating diagnostic technologies from the lab towards the point-of-use or point-of-care. Herein we discuss the current state of the field and highlight cross-disciplinary efforts to solve the challeng-es associated with the successful deployment of this important class of diagnostics at or near the point-of-care.
Funding Information
  • National Cancer Institute (UG3CA241703)
  • Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
  • ?cole Polytechnique F?d?rale de Lausanne

This publication has 145 references indexed in Scilit: